Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 (nerandomilast) thorough QT study in healthy volunteers
NCT06107036Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nerandomilast (15 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Maximum mean difference between nerandomilast and placebo in QTcF changes from baseline at 24 hours. Started Mar 2024; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT06107036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107036.